Disruption and Strategic Future for Pharma

Currently, the healthcare environment is undergoing radical changes: CMS is testing the end of manufacturers rebates, MedPAC is studying the end of Fee For Service, oncologists are challenging the deficiencies of OCM, ACO’s are challenged with at-risk reimbursement, Medicare Advantage is fielding new powers to control access to drugs and biologics, CMS Part B implementing reference pricing, and Congress is focused on drug prices. The Senate is starting to address these issues and more starting with pharmaceutical company executive testimony  and next it will be the PBMs day. SMT can help you decipher the impact of these changes and begin the discussion on how pharma should respond.

Pharmaceutical companies’ application of new science to reduce the human experience from disease, faces the translation of clinical value to consumer, provider and payer value. Not excluding market place realities of the emerging realities, we need to be sure that we face the current rate of undertreated, under tested, under diagnosed, underutilization of prevention, and poor outcomes. Does pharma have a role?  I think so, what do you think?